Lista de obras - Mark Bishton - Dominio Público Uruguay

A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).

artículo científico publicado en 2012

A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy

artículo científico publicado en 2008

A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia.

artículo científico publicado en 2013

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

scientific article published on 01 July 2019

Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independent data set

artículo científico publicado en 2008

Clinical studies of histone deacetylase inhibitors.

artículo científico publicado en 2009

Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma

scientific article published on 20 November 2006

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

artículo científico publicado en 2011

Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis

artículo científico publicado en 2015

Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Reply to Adams and Kwee.

artículo científico publicado en 2016

EBV-driven relapse of peripheral T-cell lymphoma, masquerading as a post transplant lymphoproliferative disorder following allo-SCT.

artículo científico publicado en 2013

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents

artículo científico publicado en 2007

Era-by-era improvement in survival for elderly patients with Hodgkin lymphoma; outcome data from a large population-based cohort

artículo científico publicado en 2015

Frontline management of nodular lymphocyte predominant Hodgkin lymphoma - a retrospective UK multicentre study

scientific article published on 25 July 2019

High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma

article by Mark Bishton et al published 26 February 2007 in Leukemia Research

Histone deacetylase inhibitors in lymphoma and solid malignancies

artículo científico publicado en 2008

Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide

artículo científico publicado en 2013

IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma.

artículo científico publicado en 2008

Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease

scientific article published on 01 March 2007

Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.

artículo científico publicado en 2016

Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis

artículo científico publicado en 2018

Light chain deposition disease presenting as massive hepatomegaly

scientific article published on 01 April 2010

MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi)

scientific article published on 15 October 2010

Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP

artículo científico publicado en 2019

Opsoclonus myoclonus following allogeneic haematopoietic stem cell transplantation

scientific article published on 01 November 2005

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

artículo científico publicado en 2010

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

artículo científico publicado en 2009

Population-based study of mantle cell lymphoma: Improvements in survival only seen in younger patients

artículo científico publicado en 2018

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

artículo científico publicado en 2009

Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab.

artículo científico publicado en 2008

Single-center Series of Bone Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia: High Rates of Sustained Response to Oral Methotrexate.

artículo científico publicado en 2016

Spinal epidural lipomatosis in myeloma

scientific article published on 01 October 2007

Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity

artículo científico publicado en 2019

The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling

artículo científico publicado en 2016

The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival

artículo científico publicado en 2020

The potential of histone deacetylase inhibitors for the treatment of multiple myeloma

artículo científico publicado en 2008

The role of granulocyte transfusions in neutropenic patients.

artículo científico publicado en 2004

The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naΪve patients with peripheral T-cell lymphoma: a systematic review of the literature

artículo científico publicado en 2016

What is responsible for the recent improvements in outlook for patients with follicular lymphoma?

artículo científico publicado en 2010

Lista de obras de Mark Bishton

A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).

A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy

A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia.

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independent data set

Clinical studies of histone deacetylase inhibitors.

Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis

Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Reply to Adams and Kwee.

EBV-driven relapse of peripheral T-cell lymphoma, masquerading as a post transplant lymphoproliferative disorder following allo-SCT.

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents

Era-by-era improvement in survival for elderly patients with Hodgkin lymphoma; outcome data from a large population-based cohort

Frontline management of nodular lymphocyte predominant Hodgkin lymphoma - a retrospective UK multicentre study

High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma

Histone deacetylase inhibitors in lymphoma and solid malignancies

Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide

IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma.

Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease

Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.

Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis

Light chain deposition disease presenting as massive hepatomegaly

MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi)

Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP

Opsoclonus myoclonus following allogeneic haematopoietic stem cell transplantation

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

Population-based study of mantle cell lymphoma: Improvements in survival only seen in younger patients

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab.

Single-center Series of Bone Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia: High Rates of Sustained Response to Oral Methotrexate.

Spinal epidural lipomatosis in myeloma

Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity

The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling

The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival

The potential of histone deacetylase inhibitors for the treatment of multiple myeloma

The role of granulocyte transfusions in neutropenic patients.

The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naΪve patients with peripheral T-cell lymphoma: a systematic review of the literature

What is responsible for the recent improvements in outlook for patients with follicular lymphoma?